


UK NEQAS

Leucocyte Immunophenotyping



New Information for 2027–2028

EQA/PT Programmes for
Flow Cytometry

SAVE THE DATE: 14TH JUNE 2027

UK NEQAS LI SCIENTIFIC MEETING, SHEFFIELD - REGISTRATION OPENING 2027

EQAInternational
Working in partnership with UK NEQAS LI



www.ukneqasli.co.uk

New Information for 2027–2028

EQA/PT Programmes for Flow Cytometry

Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry Accreditation

The Measurable Residual Disease (MRD) for Plasma Cell Myeloma by Flow Cytometry pilot has now completed successfully, and we have started work to bring the programme within our UKAS scope of accreditation to ISO/IEC 17043:2023.

Accreditation will give participants added confidence in how the programme is designed, assessed and reported, and in the performance benchmarking it provides. Our aim remains the same: to help laboratories produce accurate, clinically relevant MRD results for patients with myeloma.

We will share details of accreditation status, timelines and any changes to the programme as they are confirmed.

Paroxysmal Nocturnal Haemoglobinuria Quantitative Data Scoring

From 2027-2028, the Paroxysmal Nocturnal Haemoglobinuria (PNH) programme will score quantitative results alongside the existing qualitative assessment.

PNH clone size now plays a central part in patient care. It informs diagnosis, guides decisions on complement inhibitor therapy, and is used to monitor clone evolution over time. Accurate, reproducible measurements have become as important as correctly detecting a clone.

In the first phase, quantitative performance will be reported for information and education only and will not count towards performance monitoring. It will then be brought into formal performance assessment.

We will provide guidance and educational material ahead of and during the transition.

Measurable Residual Disease for Chronic Lymphocytic Leukaemia by Flow Cytometry Data Entry Page Update

The MRD for Chronic Lymphocytic Leukaemia by Flow Cytometry programme data entry page will be updated to align with the format and functionality currently used within the MRD for Acute Lymphoblastic Leukaemia and MRD Plasma Cell Myeloma by Flow Cytometry programmes.

These changes are intended to provide a more consistent user experience across MRD schemes, streamline data submission processes, and enhance reporting functionality. Guidance documentation and support materials will be provided before implementation.

SEE WEBSITE FOR FULL INFORMATION ON ALL OF THE ABOVE CHANGES

Should you wish to participate in any of the above programmes please contact:

UK NEQAS LI
Pegasus House
4th Floor Suite
463a Glossop Road
Sheffield S10 2QD
United Kingdom

Tel: +44 (0)114 2673600

Fax: +44 (0)114 2673601

email: admin@ukneqasli.co.uk

www.ukneqasli.co.uk

Please note that if your participation with UK NEQAS LI is via a non-UK distributor you should contact them directly for details of how to register. If you are enquiring from outside of the UK your registration will be managed by EQA International Ltd.